Investment in effective migraine therapy could reduce the overall costs of the disorder
Drugs Economics and Quality of Life
KeywordsMigraine Adis International Limited Risperidone Indirect Cost National Health Service
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Unable to display preview. Download preview PDF.
- 3.Parry TG. The prevalence and costs of migraine in Australia. Kensington: University of New South Wales, 1992. Centre for Applied Economic Research (CAER) working paper no.: 1992/1Google Scholar
- 6.Láinez JM, Titus F, Cobaleda S, et al. Socioeconomic impact of migraine [abstract]. Funct Neurol 1996; 11: 133Google Scholar
- 7.Björk S, Roos P. Economic aspects of migraine in Sweden. Lund: Institute for Health Economics, 1991. Working paper no.: 8Google Scholar
- 8.Blau JN, Drummond MR Migraine. Office of Health Economics (OHE). London: OHE, 1991Google Scholar
- 9.Cull RE, Wells NEJ, Miocevich ML. The economic cost of migraine. Br J Med Econ 1992; 2: 103–15Google Scholar
- 11.Streator SE, Shearer SW. Pharmacoeconomic impact of injectable sumatriptan on migraine-associated healthcare costs. Am J Manage Care 1996; 2: 139–43Google Scholar
- 13.Bloomberg Financial Markets. Electronic database. New York: LP Bloomberg, 1998Google Scholar
- 14.International Monetary Fund (IMF). International financial statistics. Vol. 11 (1). Washington, DC: IMF, 1998Google Scholar
- 15.Tailor drug choice to headache severity in acute migraine attacks. Drug Ther Perspect 1999 May 24; 13(10): 8–11Google Scholar
- 16.Alot of ammunition but does migraine prophylaxis hit the target? Drug Ther Perspect 1999 Jun 7; 13(11): 5–8Google Scholar
© Adis International Limited 1999